Morgan Stanley upgraded UCB to Equal Weight from Underweight with a price target of EUR 105, up from EUR 75. The analyst cites stronger than expected launch trends for Bimzelx to treat psoriasis for the upgrade.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
